Drug – bio-affecting and body treating compositions – Nonspecific immunoeffector – per se ; or nonspecific...
Patent
1995-05-19
1999-03-30
Cunningham, Thomas M.
Drug, bio-affecting and body treating compositions
Nonspecific immunoeffector, per se ; or nonspecific...
4242341, 4242581, 424450, 536117, A61K 3902, A61K 4505
Patent
active
058885196
ABSTRACT:
This invention is directed to the production of antibodies against lipid A by using encapsulating slow-releasing delivery materials or devices containing concentrations of lipid A that are greater than could be given safely to humans in the absence of said materials or devices. The antibodies to lipid A can be used for binding the antibodies to the lipid A that are present in the lipopolysaccharide that coats the surface of the Gram-negative bacteria.
REFERENCES:
patent: 4029762 (1977-06-01), Galanos et al.
patent: 5019394 (1991-05-01), Hamaguchi
patent: 5026557 (1991-06-01), Estis et al.
patent: 5059421 (1991-10-01), Loughrey
patent: 5059591 (1991-10-01), Janoff
Alving, C.R., et al., Immunology Letters 25:275-280 (1990), Liposomes conning lipid A: a potent nontoxic adjuvant for a human malaria sporozoite vaccine.
Dijkstra, J., et al., J. Immunology 138:2663-2670 (April 15, 1987), "Modulation of the biological activity of bacterial endotoxin by incorporation into liposomes".
Fries, L. F., et al., P.N.A.S. (USA) 89:358-362 (1992), "Liposomal malaria vaccine in humans: A safe and potent adjuvant strategy".
Herbert, W. J. in Handbook of Experimental Immunology, edited by D. M. Weir (1973), Mineral-oil adjuvants and the immunization of laboratory animals. pp. A2.1-A2.14.
Richards, R. L., et al., Infection and Immunity 56:682-686 (Mar., 1988), Liposomes, lipid A, and aluminum hydroxide enhance the immune response top a synthetic malaria sporozoite antigen.
Richards, R. L., et al., Vaccine 7:506-512 (Dec. 1989), "Immunogenicity of liposomal malaria sporozoite antigen in monkeys: adjuvant effects of aluminum hydroxide and non-pyrogenic liposomal lipid A".
Schedel, I., Infection 16:4/8-7/11 (1988), "New aspects in the treatment of Gram-negative bacteraemia and septic shock".
Schuster, B. G., et al., J. Immunology 122:900-905 (1977), "Production of antibodies against phosphocholine, phosphatidylcholine, sphingomyelin, and lipid A by injection of liposomes containing lipid A".
Fitzer-Schiller, G., Washington Post, p. D3 (Jan. 19, 1993), "Cetocor stops trials of flagship drug".
Spalding, B. J., Bio/Technology 11:428-429 (11 Apr. 1993), "In shocking Synergen, sepsis tallies third victim".
Stone, R., Science 259:1243 (26 Feb. 1993), "Biotech industry reels on sepsis drug news".
Vosika, G. J., et al., Cancer Immunology and Immunotherapy 18:107-112 (1984), Phase-I study of intravenous modified lipid A.
Wenzel, R. P., The New England Journal of Medicine 326(17):1151-1152 (Apr. 23, 1992), "Anti-endotoxin monoclonal antibodies--a second look".
Braude, A., et al. Infectious Dis. and Medical Microbiology (1986) W.B. Saunders Co. Philadelphia pp. 51-60.
Takada, H., et al. CRC Crit. Rev. Microbiol. 16(6):476-523 (1989), "Structural requirements of lipid A for endotoxicity and other biological activities".
Chedid, L. in Synthetic Vaccines, R. Arnon (ed), 787 CRC Press, Boca Raton, Fl. pp. 94-103.
Ziegler, E.J. et al. N.E.S. Med. 307(20):1225-1230. Nov. 11, 1982. "Treatmnet of Gram-negative bacteremis".
P.N. Shek, et al; Immunology 47:627-632 (1982), "Immuneresponse mediated by liposome-associated protein antigens".
Cunningham Thomas M.
Harris Charles H.
Moran John Francis
The United States of America as represented by the Secretary of
LandOfFree
Encapsulated high-concentration lipid a compositions as immunoge does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Encapsulated high-concentration lipid a compositions as immunoge, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Encapsulated high-concentration lipid a compositions as immunoge will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1211963